PTI Celebrates 25 Years in 2010
News Mar 10, 2010
Protein Technologies (PTI) celebrates its 25th anniversary this year of providing quality products and service to the global peptide community. PTI’s very first peptide synthesizer, the PS3™, celebrates its 20th anniversary in 2010 thanks to the reliability and no-nonsense operation that has come to characterize all PTI instruments since then.
A fantastic basic unit, it created such a great first impression that not only are inaugural instruments still running in some labs, but some labs refuse to buy anything else. Likewise, PTI’s SYMPHONY QUARTET™ peptide synthesizer turns 10 this year, offering an independent 4-channel instrument that can be upgraded to the full 12-channel SYMPHONY® as lab needs change.
According to Christina Chantell, PTI Chemist and Marketing Coordinator, PTI is “proud to say that our SYMPHONY® line has been the workhorse of the custom peptide industry over its lifetime.”
While the last 5 years have brought significant positive changes to the company, the result has been an amazing expanded product line including the PRELUDE™ parallel peptide synthesizer with Single-Shot deliveries and extra amino acid positions, making it perfect for synthesizing specialty peptides containing expensive or difficult-to-make monomers without priming or waste, the TRIBUTE™, a synthesizer made even with the new IntelliSynth UV-Monitoring and Feedback Control System option that automatically controls the deprotection and coupling times so the user has the best chance of getting their peptide right the first time, the SONATA® XT, an instrument that doubles the current maximum capacity of our line of synthesizers from 100 mmol to 200 mmol scale syntheses, and finally, the OVERTURE™ – PTI’s unit geared towards the robotic peptide library synthesizer market with features never before seen on robotic units in that market segment.
“We are proud of the accomplishments we have made over the last 25 years,” states Chantell, “and are eagerly looking ahead in anticipation of greater things to come.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE